China Shineway Pharmaceutical Group Limited

Shineway was selected into the pilot list of Yunnan Province’s TCM formula granules research

Shineway TCM formula Granule production capacity tripled to 2 billion bags

Shineway expects earnings for the first half of 2018 to increase by 40%

Shineway’s TCM Formula Granules added another Class III hospital

Shineway’s OTC products made their way into 780 pharmacy chains

An international medical journal published results of phase II clinical trial of Shineway’s Sai Luo Tong, revealing that it may be safe and effective for treating mild to moderate vascular dementia

Shineway’s Q1 sales of pediatric medications show strong growth

Shineway’s TCM Formula Granules have made their entrance into the People’s Hospital of Hebei Province

China Shineway Earnings Declined but Exceeded Market Expectations Increase in Dividend Payout with Positive Outlook in 2018

Shineway worked overtime throughout the Chinese New Year holiday to produce anti-flu medications

Shineway’s anti-flu medications are in hot demand and short supply

Production capacity of Shineway’s TCM formula granule has been expanded by 100%

Shineway’s exclusive product Huamoyan Granule recorded sales surge of 33%

China Shineway adds 9 oral-type Chinese medicines to its product portfolios

China Shineway Announces Interim Results for the Six Months Ended 30 June 2015 Turnover Rose by 0.9% to RMB1,109 Million Proposed Interim Dividend of RMB11 Cents per Share

China Shineway Announces Annual Results – Net Profit Reached RMB705 million, Proposed Final and Special Dividend Totaling RMB22 Cents per Share